Healthcare player Zydus Cadila (Cadila Healthcare Ltd) on Wednesday informed that the company has received final approval from the US drug regulator to market its anti-diabetic drug.
The US Food and Drug Administration (USFDA) gave its final approval to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg in the US. Glyburide, which is an anti-diabetic drug, will be produced at the Zydus Group’s formulations manufacturing facility at Baddi in Himachal Pradesh.